<DOC>
	<DOCNO>NCT01284387</DOCNO>
	<brief_summary>A Phase II clinical research study evaluate efficacy safety two different dose level injectable investigational treatment ( ACC-001 ) subject Mild-to-Moderate Alzheimer 's disease . ACC-001 ( vanutide cridificar ) beta amyloid fragment attach carrier protein . It intend help induce antibody response beta amyloid administer intramuscular injection .</brief_summary>
	<brief_title>Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Diagnosis probable AD Age 50 89 MiniMental Status Exam score 1826 inclusive Brain magnetic resonance imaging ( MRI ) scan consistent diagnosis AD Stable dose medication ( cholinesterase inhibitor memantine allow ) Caregiver able attend clinic visit patient Amyloid burden screen PET scan consistent diagnosis AD Significant neurological disease AD Major psychiatric disorder Significant systemic illness History stroke , seizure autoimmune disease History myocardial infarction within last 2 year Smoking great 20 cigarette per day Anticonvulsants , antiParkinson 's , anticoagulant , narcotic medication ( anticonvulsant use nonseizure reason allow ) Prior treatment experimental immunotherapeutics vaccine AD Women childbearing potential Presence pacemaker , CSF shunt , foreign metal object eye , skin body</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Mild moderate Alzheimer 's disease</keyword>
	<keyword>immunization</keyword>
	<keyword>amyloid imaging</keyword>
	<keyword>injection</keyword>
	<keyword>vaccine</keyword>
</DOC>